The specter of generic rivalry has long loomed over copyright’s famous drug, Viagra, sparking questions about the prospects of related medicinal holdings. While first years saw impressive returns, the exclusivity lapse has allowed the way for discounted alternatives, potentially diminishing revenue and presenting a real danger for shareholders lo